Gene · 6607
Papers3,510
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
201 to 220 of 3,510
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Mechanisms of functional improvement behind nusinersen treatment in adult spinal muscular atrophy. | Exp Neurol | 2025 | 40180233 | PubTator, text mining | PubMed |
A case of spinal muscular atrophy type 0 treated with nusinersen without progression of early-onset scoliosis - possibility of preventing scoliosis with a rehabilitation program focusing on postural management. | Brain Dev | 2025 | 40163981 | PubTator, text mining | PubMed |
| A Dual-Mode Targeted Nanopore Sequencing Assay for Comprehensive SMN1 and SMN2 Variant Analysis. | J Mol Diagn | 2025 | 40158884 | PubTator, text mining | PubMed |
| Oral and Poster Abstracts of the 13th ISNS European Regional Meeting. | Int J Neonatal Screen | 2025 | 40136636 | PubTator, text mining | PubMed |
| Long-read sequencing identifies copy-specific markers of SMN gene conversion in spinal muscular atrophy. | Genome Med | 2025 | 40119448 | PubTator, text mining | PubMed |
| Correlation Between Neuronal Apoptosis Inhibitory Protein (NAIP), SMN2, and SMA Phenotypes: A Tertiary Care Centre Experience From India. | Am J Med Genet A | 2025 | 40099840 | PubTator, text mining | PubMed |
| A de novo deletion underlying spinal muscular atrophy: implications for carrier testing and genetic counseling. | Hum Mol Genet | 2025 | 40094379 | PubTator, text mining | PubMed |
| Exploring the Prevalence of SMN1 Duplication and Deletion in Russia and Its Impact on Carrier Screening. | Int J Mol Sci | 2025 | 40076610 | PubTator, text mining | PubMed |
| Landscape of small nucleic acid therapeutics: moving from the bench to the clinic as next-generation medicines. | Signal Transduct Target Ther | 2025 | 40059188 | PubTator, text mining | PubMed |
| Mortality of symptomatic children with spinal muscular atrophy in the era of disease-modifying therapies. | Neuromuscul Disord | 2025 | 40022865 | PubTator, text mining | PubMed |
| Analysis of SMN protein in umbilical cord blood and postnatal peripheral blood of neonates with SMA: a rationale for prompt treatment initiation to prevent SMA development. | Orphanet J Rare Dis | 2025 | 40022154 | PubTator, text mining | PubMed |
| Real-world analysis of the efficacy and safety of nusinersen in pediatric patients with spinal muscular atrophy. | Orphanet J Rare Dis | 2025 | 40011938 | PubTator, text mining | PubMed |
| Three- and four-stranded nucleic acid structures and their ligands. | RSC Chem Biol | 2025 | 40007865 | PubTator, text mining | PubMed |
| Small molecules reveal differential shifts in stability and protein binding for G-quadruplex RNA. | bioRxiv | 2025 | 39990451 | PubTator, text mining | PubMed |
| Comparative study of third-generation sequencing-based CASMA-trio and STR linkage analysis for identifying SMN1 2 + 0 carriers. | Sci Rep | 2025 | 39984716 | PubTator, text mining | PubMed |
| Cost comparison analysis of onasemnogene abeparvovec and nusinersen for treatment of patients with spinal muscular atrophy type 1 in the Netherlands. | Eur J Health Econ | 2025 | 39982664 | PubTator, text mining | PubMed |
| Characterization of swallowing biomechanics and function in untreated infants with spinal muscular atrophy: A natural history dataset. | J Neuromuscul Dis | 2025 | 39973456 | PubTator, text mining | PubMed |
| Analysis of spinal muscular atrophy patients from the spinal muscular atrophy and muscular dystrophy registry of Pakistan. | J Neuromuscul Dis | 2025 | 39973405 | PubTator, text mining | PubMed |
| [Research progress on phenotypic modifier genes in spinal muscular atrophy]. | Zhongguo Dang Dai Er Ke Za Zhi | 2025 | 39962788 | PubTator, text mining | PubMed |
| The evolution and application of RNA-focused small molecule libraries. | RSC Chem Biol | 2025 | 39957993 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/6607/papers?page=11